Open

Intermediate Risk Prostate Cancer Trial

In this study, we want to learn whether more or less treatment for men with intermediate risk prostate cancer is better than the standard of care based on genetics testing results.

Age & Gender

18 years ~ 99 years
Male

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will have radiation, physical exam, questionnaires, and some blood work. You may or may not receive hormone blocking injections or chemotherapy drug due to randomization.

Total length of participation:
6 years

Looking for Specific Volunteers

Able to participate:

You have prostate cancer
Your PSA is between 10 to 20 ng/mL.

Not eligible if:

You have already received treatment for this cancer.
You have metastatic cancer.
You currently or recently have another cancer.

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

Gregg Goldin
Radiation Oncology - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Prostate)

IRB Number

23-2932

ClinicalTrials.gov

NCT05050084

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.